Vinge has represented the international private equity firm Cinven and Danish life science investment company Novo Holdings in their sale of Envirotainer Holding AB to EQT X Fund and Mubadala Investment Company, at an enterprise value of about EUR 2.8 billion. Vinge was supported by Clifford Chance.

Envirotainer develops, manufactures and leases active temperature-controlled containers, used primarily for air freighting biopharma products. The company was founded in 1985 in Stockholm and today its R&D, production and headquarters are based in the Stockholm region. With a global presence with about 375 employees in 20 countries and a fleet of about 6,500 containers, Envirotainer is the market leader in air transportation of temperature sensitive pharmaceuticals.

The Vinge team primarily consisted of Christina Kokko, Samra Baytar, Vilhelm Rondahl, Gustav Persson and Ida Redander (M&A), Victoria Gunnerek, Trine Osen Bergqvist and Ebba Thoms (EU, Competition & Regulatory), Linn Adelwald (Banking & finance), Isabell Nielsen and Sam Fakhraie Ardekani (Corporate Commercial), Sara Strandberg, Veronika Garemark, Emil Lindvall and Tove Tullberg (Employment & Corporate Crime), Kristoffer Larson (Real Estate), Axel Lennartsson and Rebecca Målquist (IP), Nicklas Thorgerzon (GDPR), Martin Boström (IT), Johan Cederblad and Lina Österberg (Permits & Environment), Viktoria Owetz Leyva, Christoffer Widström and Sara Dahlros Sköld (VDR).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026